Stock OLMA OLEMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
10.67 USD +5.96% Intraday chart for Olema Pharmaceuticals, Inc. +7.24% -23.95%
04-02 Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target MT
03-18 Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies
Olema Pharmaceuticals Insider Sold Shares Worth $269,656, According to a Recent SEC Filing
Olema Pharmaceuticals Insider Sold Shares Worth $824,134, According to a Recent SEC Filing
Olema Pharmaceuticals Insider Sold Shares Worth $196,233, According to a Recent SEC Filing
Olema Pharmaceuticals Insider Sold Shares Worth $209,296, According to a Recent SEC Filing
Olema Pharmaceuticals Insider Sold Shares Worth $117,740, According to a Recent SEC Filing
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Olema Pharmaceuticals Insider Sold Shares Worth $379,450, According to a Recent SEC Filing
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors
Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress
Olema Pharmaceuticals Says Preclinical Data Show KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Olema Pharmaceuticals Broadens Clinical Collaboration With Novartis to Increase Size of Breast Cancer Study
Top Midday Gainers
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Falling Late Thursday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OLMA Stock
  4. News Olema Pharmaceuticals, Inc.
  5. Other languages